C-reactive protein, metabolic syndrome, and insulin resistance in individuals with spinal cord injury

Journal of Spinal Cord Medicine

Volumn 28, Issue 1, 2005, Pages 20-25

  Lee, Matthew Y ^a,c   Myers, Jonathan ^a,b,c   Hayes, Amy ^a   Madan, Sherna ^a   Froelicher, Victor F ^a,b   Perkash, Inder ^a,b   Kiratli, B Jenny ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Building 7 ^*  (United States)

Author keywords

Cardiovascular disease; hsCRP; Insulin resistance; Metabolic syndrome; Paraplegia; Spinal cord injuries; Tetraplegia

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INSULIN; LIPID; BIOLOGICAL MARKER;

ANTHROPOMETRY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIET RESTRICTION; DISEASE ASSOCIATION; DYSLIPIDEMIA; FRAMINGHAM RISK SCORE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PREDICTION; REFERENCE VALUE; SCORING SYSTEM; SPINAL CORD INJURY; ADULT; BLOOD; CROSS-SECTIONAL STUDY; FEMALE; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; SPINAL CORD INJURIES;

EID: 18944407133     PISSN: 10790268     EISSN: None     Source Type: Journal    
DOI: 10.1080/10790268.2005.11753794     Document Type: Article

References (34)

1. Demirel S, Demirel C, Tukek T, et al. Risk factors for coronary heart disease in patients with spinal cord injury in Turkey. Spinal Cord. 2001;39:134-138.
2. Bauman WA, Adkins RH, Spungen AM, et al. The effect of residual neurological deficit on oral glucose tolerance in persons with chronic spinal cord injury. Spinal Cord. 1999;37:765-771.
3. Yekuteil M, Brooks ME, Ohry A, et al. The prevalence of hypertension, ischaemic heart disease, and diabetes in traumatic spinal cord injured patients and amputees. Paraplegia. 1989;27(1):58-62.
4. Bauman WA, Raza M, Spungen AM, et al. Cardiac stress testing with thallium-201 imaging reveals silent ischemia in individuals with paraplegia. Arch Phys Med Rehabil. 1994;75:946-950.
5. Bauman WA, Raza M, Chayes Z, et al. Tomographic thallium-201 myocardial perfusion imaging after intravenous dipyridamole in asymptomatic subjects with quadriplegia. Arch Phys Med Rehabil. 1993;74:740-744.
6. Ledue TB, Rifai N. High sensitivity immunoassays for C-reactive protein: promises and pitfalls. Clin Chem Lab Med. 2001;39:1171-1176.
7. Galloway A, Green HT, Windsor JJ, et al. Serial concentrations of C-reactive protein as an indicator of urinary tract infection in patients with spinal injury. J Clin Pathol. 1986;39:851-855.
8. Ledue TB, Weiner DL, Sipe JD, et al. Analytical evaluation of particle-enhanced immunoephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem. 1998;35(6):745-753.
9. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation. 2003;107:391-397.
10. Guerrero-Romero F, Rodriguez-Moran M. Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects. Diabetes Metab. 2003;29(1):65-71.
11. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
12. Garg R, Tripathy D, Dandona P. Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions. Curr Drug Targets. 2003;4:487-492.
13. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997;30:527-532.
14. Festa A, D'Agostino R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102(1):42-47.
15. Rebhun J, Madorsky JG, Glovsky MM. Proteins of the complement system and acute phase reactants in sera of patients with spinal cord injury. Ann Allergy. 1991;66:335-338.
16. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560-1566.
17. Ledue TB, Weiner DL, Sipe J, et al. Analytical evaluation of particle-enhanced immunoephelometric assays for C-reactive protein, serum amyloid A, and mannose-binding protein in human serum. Clin Chem. 1997;43:S240-S241.
18. Vigushin DM, Pepys MB, and Hawkins PN. Metabolic and scintigraphic studies of radioioginated human C-reactive protein in health and disease. J Clin Investigation. 1993;91:1351-1356.
19. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
20. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
21. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? American College of Physicians-American Society of Internal Medicine. Ann Intern Med. 1999;130:933-937.
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
23. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
24. Feinleib M, Kannel WB, Garrison RJ, et al. The Framingham Offspring Study. Design and preliminary data. Prev Med. 1975;4:518-525.
25. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
26. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003;107:327-334.
27. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007-2011.
28. Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation. 2003;107:443-447.
29. Tracy RP, Psaty BM, Macy E, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997;17:2167-2176.
30. Ford ES, Giles WH, Dietz WH. Prevalence of metabolic syndrome among US adults. JAMA. 2002;287(3):356-359.
31. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-419.
32. Wagenkenecht LE, Mayer EJ, Rewers M, et al. The Insulin Resistance Atherosclerosis Study (IRAS): objectives, design, and recruitment results. Ann Epidemiol. 1995;5:464-472.
33. Jones LM, Legge M, Goulding A. Healthy body mass index values often underestimate body fat in men with spinal cord injury. Arch Phys Med Rehabil. 2003;84:1068-1071.
34. Phillips WT, Kiratli BJ, Sarkarati M, et al. Effect of spinal cord injury on the heart and cardiovascular fitness. Curr Problems Cardiol. 1998;23:641-720.